Skip to main content

Fondaparinux Disease Interactions

There are 5 disease interactions with fondaparinux.

Major

Factor Xa inhibitors (applies to fondaparinux) bleeding

Major Potential Hazard, Moderate plausibility.

The use of factor Xa inhibitors is contraindicated in patients with active pathological bleeding as these agents increase the risk of bleeding and can cause serious or fatal hemorrhages. Caution is recommended when prescribing factor Xa inhibitors to patients at increased risk of bleeding, including patients undergoing procedures where bleeding may cause serious complications. Such patients include those undergoing spinal/epidural anesthesia or spinal puncture; these patients are at high risk of an epidural or spinal hematoma, which can result in long-term or permanent paralysis. In general, when using factor Xa inhibitors, the risk of thrombotic events should be weighed against the risk of bleeding.

References (4)
  1. (2022) "Product Information. Xarelto (rivaroxaban)." Janssen Pharmaceuticals, SUPPL-39
  2. (2020) "Product Information. Arixtra (fondaparinux)." Mylan Institutional LLC, SUPPL-43
  3. (2021) "Product Information. Eliquis (apixaban)." Bristol-Myers Squibb, SUPPL-34
  4. (2021) "Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc., SUPPL-17
Major

Fondaparinux (applies to fondaparinux) bacterial endocarditis

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infectious Endocarditis

The manufacturers state that bacterial endocarditis is a contraindication for the use of fondaparinux injection.

References (1)
  1. (2002) "Product Information. Arixtra (fondaparinux)." Organon
Major

Fondaparinux (applies to fondaparinux) renal disease

Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

The use of fondaparinux is contraindicated in patients with severe renal dysfunction (CrCl less than 30 mL/min). Fondaparinux increases the risk of bleeding in patients with renal dysfunction due to reduced clearance. This drug may cause prolonged anticoagulation in patients with CrCl 30 to 50 mL/min. Renal function should be assessed periodically during therapy, and fondaparinux should be discontinued immediately in patients who develop severe renal dysfunction while on treatment. After discontinuation of fondaparinux, its anticoagulant effects may persist for 2 to 4 days in patients with normal renal function and even longer in patients with renal dysfunction.

References (1)
  1. (2020) "Product Information. Arixtra (fondaparinux)." Mylan Institutional LLC, SUPPL-43
Moderate

Fondaparinux (applies to fondaparinux) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Patients with liver dysfunction may be vulnerable to bleeding during fondaparinux therapy; these patients should be observed closely for signs/symptoms of bleeding. No dose adjustment is recommended in patients with mild to moderate liver dysfunction. No pharmacokinetic data are available for patients with severe liver dysfunction; fondaparinux should be used cautiously in these patients.

References (1)
  1. (2020) "Product Information. Arixtra (fondaparinux)." Mylan Institutional LLC, SUPPL-43
Moderate

Fondaparinux (applies to fondaparinux) thrombocytopenia

Moderate Potential Hazard, Moderate plausibility.

Thrombocytopenia can occur with the administration of fondaparinux. Caution should be used when administered to patients with preexisting thrombocytopenia. Thrombocytopenia of any degree should be monitored closely and treatment should be discontinued if the platelet count falls below 100,000/mm3.

References (1)
  1. (2002) "Product Information. Arixtra (fondaparinux)." Organon

Switch to consumer interaction data

Fondaparinux drug interactions

There are 170 drug interactions with fondaparinux.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer